Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes
Chemotherapy, vol.54, no.5, pp.352-356, 2008 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 54 Issue: 5
- Publication Date: 2008
- Doi Number: 10.1159/000151630
- Journal Name: Chemotherapy
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.352-356
- Keywords: metastatic breast cancer, capecitabine, cisplatin, PHASE-III TRIAL, CANCER PATIENTS, 1ST-LINE CHEMOTHERAPY, THERAPY, MULTICENTER, EPIRUBICIN, DOCETAXEL, NECK, HEAD
- Lokman Hekim University Affiliated: No
Abstract
Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20-61 years of age (median 41), were included. They received Cap 2,000 mg/m2 on days 1-14 and Cisp 60 mg/m2 on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8-8.8). The median overall survival was 11.5 months (95% CI 6.9-16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline- and taxane-pretreated metastatic breast cancer patients. Copyright © 2008 S. Karger AG.